Apixaban is the anticoagulant dosed at 2.5 mg twice daily
Apixaban 2.5 mg twice daily is a reduced-dose regimen used in specific clinical scenarios, primarily in atrial fibrillation patients meeting dose-reduction criteria and for extended venous thromboembolism treatment. 1, 2, 3
Clinical Indications for Apixaban 2.5 mg BID
Atrial Fibrillation
The 2.5 mg twice daily dose is used when patients meet ≥2 of the following criteria 1, 2, 3:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (133 μmol/L)
This reduced dose maintains efficacy while minimizing bleeding risk in vulnerable populations. In the ARISTOTLE trial, apixaban (including the 2.5 mg dose in appropriate patients) demonstrated superiority over warfarin with 21% reduction in stroke/systemic embolism, 31% reduction in major bleeding, and 11% reduction in all-cause mortality 3.
For patients unsuitable for warfarin therapy, apixaban 2.5 mg twice daily may be considered as an alternative to aspirin when patients have ≥2 of the dose-reduction criteria, though this carries Class IIb evidence 1.
Extended VTE Treatment
After completing initial anticoagulation (typically 3-6 months at standard 5 mg twice daily), apixaban 2.5 mg twice daily is specifically approved for extended VTE prophylaxis 4. Recent meta-analyses demonstrate that this reduced dose provides similar protection against recurrent VTE compared to standard dosing (1.66% vs 1.78%, RR 0.94) while significantly reducing major bleeding (1.16% vs 1.96%, RR 0.62) and clinically relevant non-major bleeding 5.
Post-Left Atrial Appendage Closure
Emerging evidence supports apixaban 2.5 mg twice daily after LAAC procedures, showing superior outcomes compared to dual antiplatelet therapy with 80% reduction in composite thromboembolic events (RR 0.20) and 46% reduction in major bleeding (RR 0.54) 6.
Important Caveats
Do not confuse this with rivaroxaban 2.5 mg twice daily, which is used in a completely different context—as part of triple therapy with aspirin and clopidogrel post-PCI in AF patients 7. That rivaroxaban dose has not been validated for stroke prevention in AF.
In dialysis-dependent patients with AF, the evidence suggests standard-dose apixaban (5 mg twice daily) may be superior to the reduced 2.5 mg dose for stroke prevention, with lower mortality and similar bleeding risk 8.
The standard apixaban dose for most AF patients and initial VTE treatment remains 5 mg twice daily—only reduce to 2.5 mg when specific criteria are met 2, 3.